SyriMed
Company profile
About the company
SyriMed is a UK speciality pharmaceutical company developing, licensing, manufacturing and marketing medicines. It reformulates established molecules into liquid medicines and alternative strengths for patients who need precise dosing or have difficulty swallowing tablets. Its Ruislip research, manufacturing, quality and regulatory teams support products licensed in the United Kingdom and international markets.
Public claim
What the listing records.
“SyriMed commits to achieving net-zero emissions by 2045.”
Evidence note
The February 2026 PPN 006 plan identifies SyriMed as an SME, records 2025 as its first emissions baseline and states the 2045 target.
Source type: Public report